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RhinoplastyAbstract Objective: To evaluate the clinical efﬁcacy of remifentanil infusion in comparison with
sodium nitroprusside regarding controlled hypotension during rhinoplasty.
Background: Controlled hypotension is a well-known technique used in many operations to reduce
blood loss and need for blood transfusion and to provide satisfactory bloodless surgical ﬁeld. Many
pharmacological agents are used to perform controlled hypotension intraoperatively.
Patients and methods: A total of 130 adult consented patients of both sexes undergoing rhinoplasty
aged 20–45 years with ASA I or II, were randomized to receive remifentanil infusion
0.25–0.5 lg/kg/min (group I = 65 patients) or sodium nitroprusside 0.5 l/kg/min intraoperatively
with adjusting dose till reaching target MAP around 80 mmHg. Anesthetic technique was standard
for both groups. Time to onset of induced hypotension and time to target MAP were recorded in
addition to heart rate during induced hypotension, PaO2, PCO2 and PH together with the total
infusion dose of the hypotensive agents in both groups.
Results: Remifentanil infusion intraoperatively induces adequate hypotension with no statistical
signiﬁcant difference to that induced by sodium nitroprusside (P< 0.05).
Conclusion: This study conﬁrmed that remifentanil infusion with dose of 0.25–0.5 lg/kg/min.
induced desired controlled hypotension intraoperatively during rhinoplasty with no complications
occurred either intra- or postoperative with advantage of rapid recovery from anesthesia.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Controlled hypotension has been used to reduce bleeding and
the need for blood transfusion, and also to provide a satisfac-
tory bloodless surgical ﬁeld in many operations as in oromax-
illofacial surgery, endoscopic sinus surgery, rhinoplasty,
middle ear surgery, major orthopedic surgery (as hip or knee
Figure 2 Mean heart rate during induced hypotension in both
study groups.
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transplant surgery [1].
Controlled hypotension is deﬁned as a reduction of the sys-
tolic blood pressure to 80–90 mmHg, a reduction of mean arte-
rial pressure (MAP) to 50–65 mmHg or a 30% reduction of
baseline MAP [2]. Many pharmacological agents used for con-
trolled hypotension include those that can be used successfully
alone or in combination with others to limit dosage require-
ments and the adverse effects of each agent [3]. The common
agents that had been used are inhalational anesthetics, sodium
nitroprusside, nitroglycerin, adenosine, prostaglandin E, beta
blockers (especially esmolol), calcium channel blockers and
nacrcotics (especially remifentanil [4] (see Figs. 1–6).
Other agents may be used mainly as adjunctive as ACE
inhibitors and a2 agonists (e.g. clonidine) [5]. The main goal
of any hypotensive drug is to achieve the desired level of con-
trolled hypotension without affecting the perfusion of vital
organs and should have a rapid onset, which is easy to be
administered and disappears quickly when administration is
discontinued without toxic metabolites [6]. The new ultra-
short acting l-opioid receptor agonist (Remifentanil)
hydrochloride is known to have a hypotensive effect during a
propofol total intravenous anesthesia = TIVA, and this is
used effectively for controlled hypotension and providing a
clear dry surgical ﬁeld [7].
Sodium nitroprusside is a well-known direct vasodilator
(acting on both arterioles and venules) commonly used to
induce controlled hypotension with its high potency and short
duration of action but it has many side effects and disadvan-
tages making it is not suitable for many patients. Rebound
hypertension and increased potentials for cyanide toxicity,
and tachyarrhythmia are the common side effects [8].
The purpose of this study was to evaluate the effectiveness
of remifentanil to induce controlled hypotension as primaryFigure 1 Mean time to onset of induced hypotension and time to
target blood pressure in both study groups.
Figure 3 Change in PaO2 in both study groups. Error bars
represent 95% CI.
Figure 4 Change in PaCO2 in both study groups. Error bars
represent 95% CI.
Figure 5 Change in pH in both study groups. Error bars
represent 95% CI.
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used to induce controlled hypotension as the secondary goal.
2. Patients and methods
After approval of the local ethical committee, a total of 130
patients ASA I or II of both sexes with ages ranging from 20
to 45 years undergoing rhinoplasty were randomly divided
using closed sealed envelope method of randomization into
two groups remifentanil group (group I, n= 65 patients) or
sodium nitroprusside group (group II, n= 65 patients).
Exclusion criteria were, patients with uncontrolled hyper-
tension, severe renal or hepatic diseases, anemia age <20
and >45 years, patients who refused to participate in thisFigure 6 Method done for the ﬂowchartstudy and patients with severe ischemic heart disease or cardiac
failure.
All patients were admitted on the day before surgery and
fasted for at least 8 h before surgery. All patients received pre-
operative sedation in the form of midazolam (0.5 mg/kg) two
hours before surgery.
In all patients, a 20-gauge catheter was inserted into the left
radial artery for direct determination of arterial blood pressure
(systolic, mean, diastolic). Heart rate was continually recorded
by 5-lead ECG, also other routines were monitored in the form
of pulse oximetry, and end tidal CO2 was connected. Serial
arterial blood gas analysis was done to detect any changes in
PH or in the partial pressures of Oxygen (PaO2) and carbon
dioxide (PaCO2). Samples were taken every 30 min after the
induction of general anesthesia until 20 min in the recovery
room.
An 18-gauge cannula was inserted into a suitable vein for
ﬂuid and drug administration: Ringer’s solution was adminis-
tered continuously at a rate of 5 ml/kg/h.
3. Anesthetic technique
– In all cases, induction was done by 2 mg kg1 propofol
followed by rocurorium 0.6 mg/kg to facilitate oro-
tracheal intubation by cuffed tubes, then the patients
were connected to the mechanical ventilator to maintain
an end tidal CO2 ranging from 30 to 35 mmHg and to
ensure SpO2P 97% with 50% N2O in oxygen.
Anesthesia was maintained by Sevoﬂurane with MAC
1.5–2% and with increments of the muscle relaxant
(rocurorium) every 40 min (=0.15 mg/kg).
– After induction of anesthesia, patients received intraoper-
ative infusion according to their groups either remifen-
tanil (group I) or sodium nitroprusside (group II).to assess eligibility and randomization.
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Patients received 1 lg/kg remifentanil I.V. over 30–60 s., fol-
lowed by a continuous infusion of 0.25–0.50 lg/kg/min until
systolic blood pressure was brought within 80 mmHg, then
infusion rate was adapted to maintain hypotension at this level.
3.2. In group II
Patients received sodium nitroprusside as a continuous I.V.
infusion at a rate of 0.5 lg/kg/min until systolic blood pressure
was brought within 80 mmHg, then infusion rate was adapted
to maintain hypotension at this level.
Direct visual analysis of the surgical ﬁeld was performed
from starting surgery until the end of the surgery using the
six point scale.
In all cases, the surgeon inﬁltrated the submucosal tissue of
the nose with 1:100.000 epinephrine to minimize blood loss.
The surgeon was blinded to the hypotensive agent used, as well
as to the monitor recording the hemodynamic variables. After
the surgery, patients were recovered and were transferred to
the recovery area (PACU) for a continuous monitoring.
3.3. Statistical analysis
The required sample size has been calculated using the
G*Power software version 3.1.7 (Universita¨t Du¨sseldorf,
Germany). The primary outcome measures were the time to
onset of induced hypotension, time to target hypotension,
and heart rate during hypotension. Secondary outcomeTable 1 Category scale of intraoperative surgical ﬁeld
assessment.
0 No bleeding.
1 Slight bleeding – no suctioning required.
2 Slight bleeding – occasional suctioning required.
3 Slight bleeding – frequent suctioning required.
4 Moderate bleeding – frequent suctioning required. Bleeding
threatens the surgical ﬁeld directly after suctioning removed.
5 Severe bleeding – constant suctioning required. Bleeding
appears faster than can be removed by suction. Surgical ﬁeld
severely threatened and surgery is not possible.
Table 2 Patients’ characteristics in both study groups.
Variable Remifentanil group (n= 65)
Age (years) 30.0 (8.6)
Weight (kg) 70.9 (24.5)
Gender (M/F) 39/16
Baseline SBP (mmHg) 114 (19)
Baseline MAP (mmHg) 84 (9)
Baseline DBP (mmHg 69 (18)
Baseline heart rate (bpm) 73 (20)
Duration of anesthesia (min) 79 (32)
Data are presented as mean (SD).
a Unpaired t test.
b Pearson chi-squared test.
c Welch test.measures were the PaO2, PaCo2, and pH. It was estimated that
a sample of 65 patients in either study group would have a
power of 81% (type II error, 0.19) to detect a statistically sig-
niﬁcant difference between the two study groups for a medium
effect size of Cohen’s d= 0.5, which is equivalent to a differ-
ence of 0.5 SD in the outcome measures. This difference was
chosen as it could be regarded as a clinically relevant difference
to seek in this pilot study. This calculation used a two-sided
unpaired t test and assumed a two-tailed type I error of 0.05.
Data were analyzed using IBMª SPSSª Statistics version
22 (IBMª Corp., Armonk, NY, USA) and MedCalcª version
13 (MedCalcª Software bvba, Ostend, Belgium). Continuous
numerical variables were presented as mean and SD, and inter-
group differences were compared using the independent-
samples (unpaired) t test. The Welch test was used in place of
the t test whenever equality of variance could not be assumed.
Categorical data were presented as number and percentage and
differences were compared using the Pearson chi-squared test.
A two-sided p-value < 0.05 was considered statistically
signiﬁcant.
Our study is a non-equivalence study. So you are supposed
to use usual two-sided tests (see Table 1).
4. Results
Demographic data, duration of hypotension, duration of anes-
thesia and baseline hemodynamic data did not show any statis-
tically signiﬁcant difference among groups (Table 2). Infusion
rate and the total dose of remifentanil and nitroprusside are
shown in Table 3. There were no statistically signiﬁcant differ-
ences between both groups regarding PaO2, PaCO2 and PH
data (Table 4).
Measurements of systolic, diastolic and mean arterial pres-
sure during the period of hypotension showed no signiﬁcant
differences between both groups. Heart rate during the periods
of hypotension was signiﬁcantly lower in group (I) = remifen-
tanil group compared to group (2) = sodium nitroprusside
group (p< 0.05).
Time to reach target systolic arterial blood pressure of
80 mmHg was signiﬁcantly more in remifentanil group than in
nitroprusside group (P< 0.05) (Table 3).Therewere nopostop-
erative complications in any group and all patients were dis-
charged in the samedayof operation (after 6 hof operation end).Nitroprusside group (n= 65) p-value
29.0 (10.9) 0.580a
68.2 (26.3) 0.555a
46/19 0.853b
115 (22) 0.797a
82 (12) 0.308c
65 (19) 0.300a
75 (20) 0.569a
82 (22) 0.557c
Table 3 Details of the induced hypotension in both study groups.
Variable Remifentanil group (n= 65) Nitroprusside group (n= 65) p-value
Time to onset of induced hypotension (s) 36 (21) 55 (15) <0.0001a
Time to target blood pressure (s) 68 (15) 109 (52) <0.0001a
Duration of induced hypotension (min) 47 (13) 48 (19) 0.948a
SBP during induced hypotension (mmHg) 81 (10) 80 (10) 0.585b
MAP during induced hypotension (mmHg) 57 (4) 56 (4) 0.174b
DBP during induced hypotension (mmHg) 48 (6) 48 (6) 0.864b
Heart rate during induced hypotension (bpm) 67 (25) 90 (25) <0.0001b
Total dose of hypotensive agent (mg) 1.6 (0.6) 5.4 (2.8) <0.0001a
Infusion rate of hypotensive agent (lg/kg/min) 0.31 (0.13) 0.98 (0.61) <0.0001a
Data are presented as mean (SD).
a Welch test.
b Unpaired t test.
Table 4 Change in arterial blood gas variables in both study groups.
ABG variable Time Remifentanil group (n= 65) Nitroprusside group (n= 65) p-value
PaO2 Baseline 93 (4) 92 (5) 0.171
b
20 min 187 (33) 166 (40) 0.001a
40 min 173 (31) 180 (28) 0.187a
At PACU 141 (27) 123 (26) <0.0002a
PaCO2 Baseline 36 (2) 37 (2) 0.130
a
20 min 32 (2) 41 (3) <0.0001b
40 min 34 (3) 40 (3) <0.0001a
At PACU 40 (3) 43 (3) <0.0001a
pH Baseline 7.37 (0.16) 7.39 (0.20) 0.552b
20 min 7.41 (0.10) 7.31 (0.06) <0.0001b
40 min 7.36 (0.27) 7.29 (0.09) 0.045b
At PACU 7.34 (0.26) 7.29 (0.09) 0.142b
Data are presented as mean (SD).
a Welch test.
b Unpaired t test.
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In the present study, controlled hypotension is a well estab-
lished technique to decrease blood loss and improve surgical
visibility during rhinoplasty and also many other operations.
Many techniques have been successfully used in healthy
patients. In this study, we traced the advantage of using
Remifentanil to induce controlled hypotension rather than
the traditional use of sodium nitroprusside. The remifentanil
group showed statistically signiﬁcant decrease time to reach
target systolic arterial blood pressure (86 ± 15) after
(36 ± 12) versus sodium nitroprusside group (109 ± 55) after
(55 ± 15).
These results were also reported by other studies such as
Philip [4] who used remifentanil to induce hypotensive in total
intravenous anesthesia and also Schuttler et al. [9] who used
remifentanil in comparison with alfentanil in patients undergo-
ing major abdominal surgery.
Sodium nitroprusside also provided controlled hypotension
in the second group of patients in this study with advantages of
short duration of action, potency, and short time to reach the
target hypotension, and this result was also reported by
Boezzart and his colleagues [10], who also used nitroprusside
for inducing controlled hypotension for functional endoscopicsinus surgery in comparison with esmolol and reported that
nitroprusside is a very effective drug in inducing controlled
hypotension.
In the current study, we reported disadvantages of sodium
nitroprusside as reﬂex tachycardia which is not suitable in
patients with ischemic heart diseases, arrhythmia, tachyphy-
laxis, and also rebound hypertension which is not suitable
for already hypertensive patients. These disadvantages were
also reported by Pinaud and his colleagues [11] who used nitro-
prusside to induce hypotension in patients undergoing cran-
iotomies. Nitroprusside also involved in inducing light but
signiﬁcant hypercapnia and acidosis as previously shown in
this study, and this was also reported by Tinker and
Michenfelder [12] who did a full study on nitroprusside in
1976.
Nitroprusside is a direct vasodilator acting directly on the
vascular smooth muscle causing generalized vasodilatation
and increase cardiac output, so increasing the blood ﬂow to
the mucous membranes and to the capillaries these may lead
to increasing bleeding during surgery. This disadvantage of
nitroprusside was not reported in this study but, it is reported
by Chan et al. [13] who used nitroprusside to induce hypoten-
sion in patients undergoing anterior maxillary osteotomy
who revealed disadvantages of nitroprusside in the form of
308 E.M.K. Aboseif, S.M. Osmandegradation by light, cyanide toxicity and the need for invasive
blood pressure measurement.
6. Conclusion and recommendations
The present study showed that remifentanil infusion was inter-
esting in providing controlled hypotension as well as dry surgi-
cal ﬁeld in patients undergoing rhinoplasty with no need for
additional use of a potent hypotensive agent. Further studies
on large scale are recommended to conﬁrm these results.
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